Lupin's Nagpur facility receives EIR from US FDA

Lupin Limited (Lupin) announced that the United States Food and Drug Administration (US FDA) has approved the Establishment Inspection Report (EIR) for its new injectable facility in Nagpur. According to the firm, the EIR was issued following the facility's most recent inspection, which took place from October 17, 2022 to October 29, 2022. "We are very happy to have received the EIR for our Nagpur injectable facility from the US FDA," said Nilesh Gupta, Managing Director, Lupin.

"Our cutting-edge injectable facility in Nagpur is built to the highest quality standards and adheres to international regulations, using cutting-edge technology and equipment. We are committed to bringing an important portfolio of injectables that address the facility's unmet needs "He went on to say. Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.